[A25-14] Sotatercept (pulmonary arterial hypertension) – Addendum to Project A24-96
Last updated 06.03.2025
Project no.:
A25-14
Commission:
Commission awarded on 28.01.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Treatment of pulmonary arterial hypertension in adult patients with WHO Functional Class II to III, to improve exercise capacity
unchanged after addendum: Added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-14_en
| Project no. | Title | Status |
|---|---|---|
| A24-96 | Sotatercept (pulmonary arterial hypertension) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-03-06 A G-BA decision was published.